(Q46611178)

23 December 2017

title

Phase II study of perifosine in previously untreated patients with metastatic melanoma (English)

1 reference

23 December 2017

1 reference

D Scott Ernst

1

1 reference

23 December 2017

Elizabeth Eisenhauer

2

1 reference

23 December 2017

Nancy Wainman

3

1 reference

23 December 2017

Mary Davis

4

1 reference

23 December 2017

Reinhard Lohmann

5

1 reference

23 December 2017

Tara Baetz

6

1 reference

23 December 2017

Karl Belanger

7

1 reference

23 December 2017

Michael Smylie

8

1 reference

23 December 2017

publication date

1 December 2005

1 reference

23 December 2017

Investigational New Drugs

published in

1 reference

23 December 2017

volume

23

1 reference

23 December 2017

page(s)

569-575

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1007/s10637-005-1157-4

exact match

0 references

cites work

The inhibition of cell signaling pathways by antitumor ether lipids

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-005-1157-4

Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest

21 January 2018

1 reference

12 December 2020

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Alkylphospholipids reversibly open epithelial tight junctions

1 reference

12 December 2020

Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities

1 reference

12 December 2020

The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.

1 reference

12 December 2020

Melanomas, from the cell cycle point of view (Review)

1 reference

12 December 2020

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

12 December 2020

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

1 reference

12 December 2020

Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/cip1) promoter by Sp1.

1 reference

12 December 2020

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

1 reference

12 December 2020

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

1 reference

12 December 2020

D-21266, a new heterocyclic alkylphospholipid with antitumour activity

1 reference

12 December 2020

Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine

1 reference

12 December 2020

Multinomial phase II trial designs.

1 reference

12 December 2020

Application of a new multinomial phase II stopping rule using response and early progression.

1 reference

12 December 2020

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update

1 reference

12 December 2020

Metabolism of ether phospholipids and analogs in neoplastic cells

1 reference

12 December 2020

10.1007/S10637-005-1157-4

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

16034524

1 reference

23 December 2017